Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMP012/AS01B vaccine in healthy malaria-naïve adults
NCT02174978Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Aug 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of FMP012 in malaria, sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Number of solicited adverse events at 7 days. Started Aug 2014; status: completed.
02
Drugs
FMP012
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02174978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174978.